The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression

#1394

Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.

Aim(s): The optimal methods to assess tumour response to PRRT remains unclear.

Materials and methods: We present the case of a forty-nine year old male with a grade 2 (KI-67 4.7%) well-differentiated metastatic rectal neuroendocrine carcinoma with liver, lymph node and bone metastases. All tumours were gallium DOTATATE avid but had previously enlarged on somatostatin analogue therapy.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Ladwa R

Authors: Ladwa R, Lyle M, Wyld D, Burge M,

Keywords: Peptide Receptor Radionucleotide Therapy, Pseudoprogression, Neuroendocrine Carcinoma ,